CAMBRIDGE, England and MONTREAL, March 19, 2026 /PRNewswire/ -- CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre (R) Lung ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
Researchers at the University of Gothenburg, Sweden, have identified a protein linked to an increased risk of metastasis and ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
The researchers found higher ATF4 levels in tumors from older subjects, both in mice and in human patients. Elevated ATF4 was also linked to a greater chance of cancer returning after lung surgery and ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
In the quest for more targeted lung cancer treatments, a researcher at the University of Missouri thinks the solution may lie in tiny bubble-shaped packages that cells use to talk to each other. These ...
In a recent opinion piece published in the journal Trends in Cancer, researchers examined the rising global burden of lung cancer in people with no history of smoking. This phenomenon requires its own ...
CellCarta and Biofidelity today announce an expanded multi-year global strategic partnership, including exclusivity for Aspyre® Lung in clinical trial settings.
The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results